Retatrutide, by Soma Pharmaceuticals , is attracting considerable attention as a potential treatment for obesity management . This unique drug merges the mechanism of a GLP-1 receptor stimulant and a GIP receptor activator , designed to simply promote reduced body fat but also target associated metabolic issues . Initial clinical studies have indic